Baloise H1 profit jumps 25% on non-life strength ahead of Helvetia merger

Baloise Group reported a robust first half of 2025, with net profit climbing 25.5% to CHF 275.9 million and operating profit rising 31.8%, primarily driven by strong performance in its non-life business and increased investment income, despite a decline in life premiums. Concurrently, the company is progressing with its shareholder-approved merger with Helvetia, expected to close in Q4 pending regulatory approvals, which will establish Helvetia Baloise Holding Ltd as Switzerland's second-largest insurance group with CHF 20 billion in business volume and projected annual synergies of CHF 350 million. Baloise shares gained 14% in H1, and the dividend was raised.

Analysis

Baloise Group demonstrated robust financial performance in the first half of 2025, with net profit increasing 25.5% to CHF 275.9 million, driven primarily by its non-life insurance business. The non-life segment's EBIT surged 85.6%, and its combined ratio improved significantly to 90.6% from 93.2%, indicating enhanced underwriting profitability despite absorbing CHF 46.5 million in natural catastrophe claims. This strength offset notable weakness in the life insurance division, where gross premiums fell 10.8% and the new business margin contracted to 3.9% from 5.7%. The group's capital position strengthened, evidenced by a Swiss Solvency Test (SST) ratio improvement to approximately 215% from 204%, even as shareholder equity saw a minor decline. The key forward-looking catalyst is the pending merger with Helvetia, which has received shareholder approval and is expected to close in Q4. This transaction is poised to create Switzerland's second-largest insurance group and targets substantial annual synergies of around CHF 350 million, providing a clear path for future value creation. The market has responded positively, with the stock gaining 14% in H1 and the dividend being increased by 5.2%.

Key Decisions for Investors

• Investors should view the strong non-life results and improved SST solvency ratio as a validation of the company's core operational health and risk management.
• The primary risk to monitor is the persistent weakness in the life insurance segment, particularly the declining premium volume and contracting new business margins, which could drag on future profitability.
• The upcoming merger with Helvetia is the most significant catalyst; investors should closely track the progress of the Q4 regulatory approvals and the subsequent execution of the integration to realize the projected CHF 350 million in synergies.